首页/数据集/Antagonizing miR-128 abrogates chemoresistance-associated metastasis and is therapeutic in non-small cell lung cancer

Antagonizing miR-128 abrogates chemoresistance-associated metastasis and is therapeutic in non-small cell lung cancer

ChEBI2015-04-10 更新2026-07-21 收录

非小细胞肺癌治疗

化疗耐药机制

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-67729 数据链接链接失效反馈

官方服务：

资源简介：

Antagonizing miR-128 abrogates chemoresistance-associated metastasis and is therapeutic in non-small cell lung cancer

应用场景：

创建时间：

2015-04-10

化疗耐药机制

ATR抑制剂联合疗法

The ataxia-telangiectasia-mutated (ATM) and rad3-related (ATR) checkpoint pathway plays an essential role in modulating cellular responses to replication stress and DNA damage to maintain genomic stab

NIAID Data Ecosystem60

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

非小细胞肺癌治疗

MET抑制剂

aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of AL

Taylor & Francis Group2021-05-07 更新40

DataSheet13_Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.zip

抗肿瘤药物开发

非小细胞肺癌治疗

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. Howeve

NIAID Data Ecosystem20

Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy

化疗耐药机制

IFN-γ信号通路

"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,

NIAID Data Ecosystem40

Dataset from Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.

非小细胞肺癌治疗

EGFR-TKI耐药性

The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dos

NIAID Data Ecosystem30

Antagonizing miR-128 abrogates chemoresistance-associated metastasis and is therapeutic in non-small cell lung cancer

资源简介：

相关数据集